Preclinical pathology software
Open for applications
Preclinical pathology software
101-200 employees
Open for applications
101-200 employees
Deciphex's mission is to enable users to facilitate digital peer review of non-clinical pathology studies.
Pathologists are the core of diagnostics, but have been under increasing pressure in recent years with cancer cases rising, diagnostic complexity increasing, and the number of pathologists in decline. This systemic strain has meant turnaround times for diagnoses are longer, and the chance of diagnostic error is higher. Deciphex is looking to help address this, starting with its flagship regulated non-clinical pathology platform Patholytix.
Deciphex has institutional and headline support, is supported as a High Potential Startup by Ireland, has collaborated with AstraZeneca and Janssen, and participates in a research program with pharmaceutical company Charles River. Reports suggest the platform has seen impressive uptake in the preclinical sector, so in spite of being relatively young this specialist niche is in high demand.
This all means Deciphex is in a strong position to keep expanding out its suite of tools and platforms and, with Ireland’s lively and well-funded MedTech scene, the company has found no problems securing financial support. Its latest round of funding will go towards increasing headcount and expanding its presence across territories, as well as fuelling further research and development.
Steph
Company Specialist at Welcome to the Jungle
Jan 2023
$4.3m
LATE VC
May 2022
$11.5m
SERIES B
Botanic, Dublin, D
Donal O’Shea
(Chief Executive)Has experience founding three companies prior to Deciphex, and has senior management experience in Slidepath, Genetix, Leica Microsystems and Leica Biosystems.
Share this job
View 8 more jobs at Deciphex